Paul Negulescu, SVP and disease area executive for Vertex's pain program
Q&A: Vertex’s pain research chief on moving beyond opioids, AI and how pharma acquisitions thrive or fail
SAN DIEGO — For savvy dealmaking, Vertex’s 2001 acquisition of Aurora Biosciences is near the top of the list.
Vertex bought the San Diego biotech for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
